Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Identifieur interne : 001A58 ( Main/Exploration ); précédent : 001A57; suivant : 001A59Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Auteurs : Arlene Chan [Australie] ; Suzette Delaloge [France] ; Frankie A. Holmes [États-Unis] ; Beverly Moy [États-Unis] ; Hiroji Iwata [Japon] ; Vernon J. Harvey [Nouvelle-Zélande] ; Nicholas J. Robert [États-Unis] ; Tajana Silovski [Croatie] ; Erhan Gokmen [Turquie] ; Gunter Von Minckwitz [Allemagne] ; Bent Ejlertsen [Danemark] ; Stephen K L. Chia [Canada] ; Janine Mansi [Royaume-Uni] ; Carlos H. Barrios [Brésil] ; Michael Gnant [Autriche] ; Marc Buyse [Belgique] ; Ira Gore [États-Unis] ; John Smith [États-Unis] ; Graydon Harker [États-Unis] ; Norikazu Masuda [Japon] ; Katarina Petrakova [République tchèque] ; Angel Guerrero Zotano [Espagne] ; Nicholas Iannotti [États-Unis] ; Gladys Rodriguez [États-Unis] ; Pierfrancesco Tassone [Italie] ; Alvin Wong [États-Unis] ; Richard Bryce [États-Unis] ; Yining Ye [États-Unis] ; Bin Yao [États-Unis] ; Miguel Martin [Espagne]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Calendrier d'administration des médicaments, Estimation de Kaplan-Meier, Femelle, Humains, Internationalité, Invasion tumorale (anatomopathologie), Mastectomie (), Modèles de hasards proportionnels, Méthode en double aveugle, Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Quinoléines (administration et posologie), Quinoléines (effets indésirables), Relation dose-effet des médicaments, Récepteur ErbB-2 (métabolisme), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Survie sans rechute, Traitement médicamenteux adjuvant, Trastuzumab (administration et posologie), Trastuzumab (effets indésirables), Tumeurs du sein (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (mortalité), Tumeurs du sein (traitement médicamenteux), Études de suivi.
- MESH :
- administration et posologie : Protocoles de polychimiothérapie antinéoplasique, Quinoléines, Trastuzumab.
- anatomopathologie : Invasion tumorale, Tumeurs du sein.
- effets indésirables : Quinoléines, Trastuzumab.
- mortalité : Tumeurs du sein.
- métabolisme : Récepteur ErbB-2.
- traitement médicamenteux : Tumeurs du sein.
- Adulte, Adulte d'âge moyen, Analyse de survie, Calendrier d'administration des médicaments, Estimation de Kaplan-Meier, Femelle, Humains, Internationalité, Mastectomie, Modèles de hasards proportionnels, Méthode en double aveugle, Relation dose-effet des médicaments, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Survie sans rechute, Traitement médicamenteux adjuvant, Tumeurs du sein, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Breast Neoplasms (drug therapy), Breast Neoplasms (mortality), Breast Neoplasms (pathology), Breast Neoplasms (surgery), Chemotherapy, Adjuvant, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Internationality, Kaplan-Meier Estimate, Mastectomy (methods), Middle Aged, Neoplasm Invasiveness (pathology), Neoplasm Staging, Proportional Hazards Models, Quinolines (administration & dosage), Quinolines (adverse effects), Receptor, ErbB-2 (metabolism), Survival Analysis, Trastuzumab (administration & dosage), Trastuzumab (adverse effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Quinolines, Trastuzumab.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , adverse effects : Quinolines, Trastuzumab.
- drug therapy : Breast Neoplasms.
- chemical , metabolism : Receptor, ErbB-2.
- methods : Mastectomy.
- mortality : Breast Neoplasms.
- pathology : Breast Neoplasms, Neoplasm Invasiveness.
- surgery : Breast Neoplasms.
- Adult, Aged, Chemotherapy, Adjuvant, Disease-Free Survival, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Internationality, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Proportional Hazards Models, Survival Analysis, Treatment Outcome.
Abstract
Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.
DOI: 10.1016/S1470-2045(15)00551-3
PubMed: 26874901
Affiliations:
- Allemagne, Australie, Autriche, Belgique, Brésil, Canada, Croatie, Danemark, Espagne, France, Italie, Japon, Nouvelle-Zélande, Royaume-Uni, République tchèque, Turquie, États-Unis
- Alabama, Angleterre, Californie, Communauté de Madrid, Floride, Grand Londres, Hovedstaden, Massachusetts, Moravie, Rio Grande do Sul, Texas, Utah, Vienne (Autriche), Virginie
- Brno, Copenhague, Londres, Madrid, Porto Alegre, Vienne (Autriche)
- Université complutense de Madrid
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002129
- to stream PubMed, to step Curation: 002103
- to stream PubMed, to step Checkpoint: 002103
- to stream Ncbi, to step Merge: 003131
- to stream Ncbi, to step Curation: 003131
- to stream Ncbi, to step Checkpoint: 003131
- to stream Main, to step Merge: 001A54
- to stream Main, to step Curation: 001A58
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</title><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Holmes, Frankie A" sort="Holmes, Frankie A" uniqKey="Holmes F" first="Frankie A" last="Holmes">Frankie A. Holmes</name><affiliation wicri:level="2"><nlm:affiliation>Texas Oncology, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Oncology, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Moy, Beverly" sort="Moy, Beverly" uniqKey="Moy B" first="Beverly" last="Moy">Beverly Moy</name><affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name><affiliation wicri:level="1"><nlm:affiliation>Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Aichi Cancer Center, Chikusa-ku, Nagoya</wicri:regionArea><wicri:noRegion>Nagoya</wicri:noRegion></affiliation></author><author><name sortKey="Harvey, Vernon J" sort="Harvey, Vernon J" uniqKey="Harvey V" first="Vernon J" last="Harvey">Vernon J. Harvey</name><affiliation wicri:level="1"><nlm:affiliation>Auckland Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Robert, Nicholas J" sort="Robert, Nicholas J" uniqKey="Robert N" first="Nicholas J" last="Robert">Nicholas J. Robert</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Silovski, Tajana" sort="Silovski, Tajana" uniqKey="Silovski T" first="Tajana" last="Silovski">Tajana Silovski</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital For Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.</nlm:affiliation><country xml:lang="fr">Croatie</country><wicri:regionArea>University Hospital For Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb</wicri:regionArea><wicri:noRegion>Zagreb</wicri:noRegion></affiliation></author><author><name sortKey="Gokmen, Erhan" sort="Gokmen, Erhan" uniqKey="Gokmen E" first="Erhan" last="Gokmen">Erhan Gokmen</name><affiliation wicri:level="1"><nlm:affiliation>Ege University Faculty of Medicine, Izmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Ege University Faculty of Medicine, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation></author><author><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name><affiliation wicri:level="1"><nlm:affiliation>Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg</wicri:regionArea><wicri:noRegion>Neu-lsenburg</wicri:noRegion><wicri:noRegion>Neu-lsenburg</wicri:noRegion><wicri:noRegion>Neu-lsenburg</wicri:noRegion></affiliation></author><author><name sortKey="Ejlertsen, Bent" sort="Ejlertsen, Bent" uniqKey="Ejlertsen B" first="Bent" last="Ejlertsen">Bent Ejlertsen</name><affiliation wicri:level="3"><nlm:affiliation>Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Chia, Stephen K L" sort="Chia, Stephen K L" uniqKey="Chia S" first="Stephen K L" last="Chia">Stephen K L. Chia</name><affiliation wicri:level="1"><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC Cancer Agency, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mansi, Janine" sort="Mansi, Janine" uniqKey="Mansi J" first="Janine" last="Mansi">Janine Mansi</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H" last="Barrios">Carlos H. Barrios</name><affiliation wicri:level="3"><nlm:affiliation>Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre</wicri:regionArea><placeName><settlement type="city">Porto Alegre</settlement><region type="state">Rio Grande do Sul</region></placeName></affiliation></author><author><name sortKey="Gnant, Michael" sort="Gnant, Michael" uniqKey="Gnant M" first="Michael" last="Gnant">Michael Gnant</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name><affiliation wicri:level="1"><nlm:affiliation>International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>International Drug Development Institute (IDDI), Louvain-la-Neuve</wicri:regionArea><wicri:noRegion>Louvain-la-Neuve</wicri:noRegion></affiliation></author><author><name sortKey="Gore, Ira" sort="Gore, Ira" uniqKey="Gore I" first="Ira" last="Gore">Ira Gore</name><affiliation wicri:level="2"><nlm:affiliation>Alabama Oncology, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alabama Oncology, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Smith, John" sort="Smith, John" uniqKey="Smith J" first="John" last="Smith">John Smith</name><affiliation wicri:level="2"><nlm:affiliation>Northwest Cancer Specialists, Vancouver, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwest Cancer Specialists, Vancouver, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Harker, Graydon" sort="Harker, Graydon" uniqKey="Harker G" first="Graydon" last="Harker">Graydon Harker</name><affiliation wicri:level="2"><nlm:affiliation>Utah Cancer Specialists, Salt Lake City, UT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Utah Cancer Specialists, Salt Lake City, UT</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name><affiliation wicri:level="1"><nlm:affiliation>National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Petrakova, Katarina" sort="Petrakova, Katarina" uniqKey="Petrakova K" first="Katarina" last="Petrakova">Katarina Petrakova</name><affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Zotano, Angel Guerrero" sort="Zotano, Angel Guerrero" uniqKey="Zotano A" first="Angel Guerrero" last="Zotano">Angel Guerrero Zotano</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Valenciano de Oncologia, València, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto Valenciano de Oncologia, València</wicri:regionArea><wicri:noRegion>València</wicri:noRegion></affiliation></author><author><name sortKey="Iannotti, Nicholas" sort="Iannotti, Nicholas" uniqKey="Iannotti N" first="Nicholas" last="Iannotti">Nicholas Iannotti</name><affiliation wicri:level="2"><nlm:affiliation>Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Rodriguez, Gladys" sort="Rodriguez, Gladys" uniqKey="Rodriguez G" first="Gladys" last="Rodriguez">Gladys Rodriguez</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Oncology and Hematology, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>South Texas Oncology and Hematology, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Tassone, Pierfrancesco" sort="Tassone, Pierfrancesco" uniqKey="Tassone P" first="Pierfrancesco" last="Tassone">Pierfrancesco Tassone</name><affiliation wicri:level="1"><nlm:affiliation>Magna Graecia University, Catanzaro, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Magna Graecia University, Catanzaro</wicri:regionArea><wicri:noRegion>Catanzaro</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Alvin" sort="Wong, Alvin" uniqKey="Wong A" first="Alvin" last="Wong">Alvin Wong</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bryce, Richard" sort="Bryce, Richard" uniqKey="Bryce R" first="Richard" last="Bryce">Richard Bryce</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ye, Yining" sort="Ye, Yining" uniqKey="Ye Y" first="Yining" last="Ye">Yining Ye</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yao, Bin" sort="Yao, Bin" uniqKey="Yao B" first="Bin" last="Yao">Bin Yao</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name><affiliation wicri:level="4"><nlm:affiliation>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region><settlement type="city">Madrid</settlement></placeName><orgName type="university">Université complutense de Madrid</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26874901</idno><idno type="pmid">26874901</idno><idno type="doi">10.1016/S1470-2045(15)00551-3</idno><idno type="wicri:Area/PubMed/Corpus">002129</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002129</idno><idno type="wicri:Area/PubMed/Curation">002103</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002103</idno><idno type="wicri:Area/PubMed/Checkpoint">002103</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002103</idno><idno type="wicri:Area/Ncbi/Merge">003131</idno><idno type="wicri:Area/Ncbi/Curation">003131</idno><idno type="wicri:Area/Ncbi/Checkpoint">003131</idno><idno type="wicri:Area/Main/Merge">001A54</idno><idno type="wicri:Area/Main/Curation">001A58</idno><idno type="wicri:Area/Main/Exploration">001A58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</title><author><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name><affiliation wicri:level="1"><nlm:affiliation>Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Holmes, Frankie A" sort="Holmes, Frankie A" uniqKey="Holmes F" first="Frankie A" last="Holmes">Frankie A. Holmes</name><affiliation wicri:level="2"><nlm:affiliation>Texas Oncology, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Texas Oncology, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Moy, Beverly" sort="Moy, Beverly" uniqKey="Moy B" first="Beverly" last="Moy">Beverly Moy</name><affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name><affiliation wicri:level="1"><nlm:affiliation>Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Aichi Cancer Center, Chikusa-ku, Nagoya</wicri:regionArea><wicri:noRegion>Nagoya</wicri:noRegion></affiliation></author><author><name sortKey="Harvey, Vernon J" sort="Harvey, Vernon J" uniqKey="Harvey V" first="Vernon J" last="Harvey">Vernon J. Harvey</name><affiliation wicri:level="1"><nlm:affiliation>Auckland Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Robert, Nicholas J" sort="Robert, Nicholas J" uniqKey="Robert N" first="Nicholas J" last="Robert">Nicholas J. Robert</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Silovski, Tajana" sort="Silovski, Tajana" uniqKey="Silovski T" first="Tajana" last="Silovski">Tajana Silovski</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital For Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.</nlm:affiliation><country xml:lang="fr">Croatie</country><wicri:regionArea>University Hospital For Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb</wicri:regionArea><wicri:noRegion>Zagreb</wicri:noRegion></affiliation></author><author><name sortKey="Gokmen, Erhan" sort="Gokmen, Erhan" uniqKey="Gokmen E" first="Erhan" last="Gokmen">Erhan Gokmen</name><affiliation wicri:level="1"><nlm:affiliation>Ege University Faculty of Medicine, Izmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Ege University Faculty of Medicine, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation></author><author><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name><affiliation wicri:level="1"><nlm:affiliation>Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg</wicri:regionArea><wicri:noRegion>Neu-lsenburg</wicri:noRegion><wicri:noRegion>Neu-lsenburg</wicri:noRegion><wicri:noRegion>Neu-lsenburg</wicri:noRegion></affiliation></author><author><name sortKey="Ejlertsen, Bent" sort="Ejlertsen, Bent" uniqKey="Ejlertsen B" first="Bent" last="Ejlertsen">Bent Ejlertsen</name><affiliation wicri:level="3"><nlm:affiliation>Rigshospitalet, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Rigshospitalet, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Chia, Stephen K L" sort="Chia, Stephen K L" uniqKey="Chia S" first="Stephen K L" last="Chia">Stephen K L. Chia</name><affiliation wicri:level="1"><nlm:affiliation>BC Cancer Agency, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC Cancer Agency, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mansi, Janine" sort="Mansi, Janine" uniqKey="Mansi J" first="Janine" last="Mansi">Janine Mansi</name><affiliation wicri:level="3"><nlm:affiliation>Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H" last="Barrios">Carlos H. Barrios</name><affiliation wicri:level="3"><nlm:affiliation>Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre</wicri:regionArea><placeName><settlement type="city">Porto Alegre</settlement><region type="state">Rio Grande do Sul</region></placeName></affiliation></author><author><name sortKey="Gnant, Michael" sort="Gnant, Michael" uniqKey="Gnant M" first="Michael" last="Gnant">Michael Gnant</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name><affiliation wicri:level="1"><nlm:affiliation>International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>International Drug Development Institute (IDDI), Louvain-la-Neuve</wicri:regionArea><wicri:noRegion>Louvain-la-Neuve</wicri:noRegion></affiliation></author><author><name sortKey="Gore, Ira" sort="Gore, Ira" uniqKey="Gore I" first="Ira" last="Gore">Ira Gore</name><affiliation wicri:level="2"><nlm:affiliation>Alabama Oncology, Birmingham, AL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Alabama Oncology, Birmingham, AL</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Smith, John" sort="Smith, John" uniqKey="Smith J" first="John" last="Smith">John Smith</name><affiliation wicri:level="2"><nlm:affiliation>Northwest Cancer Specialists, Vancouver, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwest Cancer Specialists, Vancouver, VA</wicri:regionArea><placeName><region type="state">Virginie</region></placeName></affiliation></author><author><name sortKey="Harker, Graydon" sort="Harker, Graydon" uniqKey="Harker G" first="Graydon" last="Harker">Graydon Harker</name><affiliation wicri:level="2"><nlm:affiliation>Utah Cancer Specialists, Salt Lake City, UT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Utah Cancer Specialists, Salt Lake City, UT</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name><affiliation wicri:level="1"><nlm:affiliation>National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka</wicri:regionArea><wicri:noRegion>Osaka</wicri:noRegion></affiliation></author><author><name sortKey="Petrakova, Katarina" sort="Petrakova, Katarina" uniqKey="Petrakova K" first="Katarina" last="Petrakova">Katarina Petrakova</name><affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea><placeName><settlement type="city">Brno</settlement><region>Moravie</region></placeName></affiliation></author><author><name sortKey="Zotano, Angel Guerrero" sort="Zotano, Angel Guerrero" uniqKey="Zotano A" first="Angel Guerrero" last="Zotano">Angel Guerrero Zotano</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Valenciano de Oncologia, València, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto Valenciano de Oncologia, València</wicri:regionArea><wicri:noRegion>València</wicri:noRegion></affiliation></author><author><name sortKey="Iannotti, Nicholas" sort="Iannotti, Nicholas" uniqKey="Iannotti N" first="Nicholas" last="Iannotti">Nicholas Iannotti</name><affiliation wicri:level="2"><nlm:affiliation>Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Rodriguez, Gladys" sort="Rodriguez, Gladys" uniqKey="Rodriguez G" first="Gladys" last="Rodriguez">Gladys Rodriguez</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Oncology and Hematology, San Antonio, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>South Texas Oncology and Hematology, San Antonio, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Tassone, Pierfrancesco" sort="Tassone, Pierfrancesco" uniqKey="Tassone P" first="Pierfrancesco" last="Tassone">Pierfrancesco Tassone</name><affiliation wicri:level="1"><nlm:affiliation>Magna Graecia University, Catanzaro, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Magna Graecia University, Catanzaro</wicri:regionArea><wicri:noRegion>Catanzaro</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Alvin" sort="Wong, Alvin" uniqKey="Wong A" first="Alvin" last="Wong">Alvin Wong</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bryce, Richard" sort="Bryce, Richard" uniqKey="Bryce R" first="Richard" last="Bryce">Richard Bryce</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Ye, Yining" sort="Ye, Yining" uniqKey="Ye Y" first="Yining" last="Ye">Yining Ye</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yao, Bin" sort="Yao, Bin" uniqKey="Yao B" first="Bin" last="Yao">Bin Yao</name><affiliation wicri:level="2"><nlm:affiliation>Puma Biotechnology, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Puma Biotechnology, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name><affiliation wicri:level="4"><nlm:affiliation>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region><settlement type="city">Madrid</settlement></placeName><orgName type="university">Université complutense de Madrid</orgName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (mortality)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (surgery)</term><term>Chemotherapy, Adjuvant</term><term>Disease-Free Survival</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Internationality</term><term>Kaplan-Meier Estimate</term><term>Mastectomy (methods)</term><term>Middle Aged</term><term>Neoplasm Invasiveness (pathology)</term><term>Neoplasm Staging</term><term>Proportional Hazards Models</term><term>Quinolines (administration & dosage)</term><term>Quinolines (adverse effects)</term><term>Receptor, ErbB-2 (metabolism)</term><term>Survival Analysis</term><term>Trastuzumab (administration & dosage)</term><term>Trastuzumab (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Calendrier d'administration des médicaments</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Internationalité</term><term>Invasion tumorale (anatomopathologie)</term><term>Mastectomie ()</term><term>Modèles de hasards proportionnels</term><term>Méthode en double aveugle</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Quinoléines (administration et posologie)</term><term>Quinoléines (effets indésirables)</term><term>Relation dose-effet des médicaments</term><term>Récepteur ErbB-2 (métabolisme)</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term><term>Trastuzumab (administration et posologie)</term><term>Trastuzumab (effets indésirables)</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (mortalité)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Quinolines</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Quinoléines</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Quinolines</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Invasion tumorale</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Quinoléines</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mastectomy</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteur ErbB-2</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Neoplasm Invasiveness</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chemotherapy, Adjuvant</term><term>Disease-Free Survival</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Internationality</term><term>Kaplan-Meier Estimate</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Proportional Hazards Models</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Calendrier d'administration des médicaments</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Internationalité</term><term>Mastectomie</term><term>Modèles de hasards proportionnels</term><term>Méthode en double aveugle</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs du sein</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Brésil</li><li>Canada</li><li>Croatie</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Italie</li><li>Japon</li><li>Nouvelle-Zélande</li><li>Royaume-Uni</li><li>République tchèque</li><li>Turquie</li><li>États-Unis</li></country><region><li>Alabama</li><li>Angleterre</li><li>Californie</li><li>Communauté de Madrid</li><li>Floride</li><li>Grand Londres</li><li>Hovedstaden</li><li>Massachusetts</li><li>Moravie</li><li>Rio Grande do Sul</li><li>Texas</li><li>Utah</li><li>Vienne (Autriche)</li><li>Virginie</li></region><settlement><li>Brno</li><li>Copenhague</li><li>Londres</li><li>Madrid</li><li>Porto Alegre</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université complutense de Madrid</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Chan, Arlene" sort="Chan, Arlene" uniqKey="Chan A" first="Arlene" last="Chan">Arlene Chan</name></noRegion></country><country name="France"><noRegion><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="Holmes, Frankie A" sort="Holmes, Frankie A" uniqKey="Holmes F" first="Frankie A" last="Holmes">Frankie A. Holmes</name></region><name sortKey="Bryce, Richard" sort="Bryce, Richard" uniqKey="Bryce R" first="Richard" last="Bryce">Richard Bryce</name><name sortKey="Gore, Ira" sort="Gore, Ira" uniqKey="Gore I" first="Ira" last="Gore">Ira Gore</name><name sortKey="Harker, Graydon" sort="Harker, Graydon" uniqKey="Harker G" first="Graydon" last="Harker">Graydon Harker</name><name sortKey="Iannotti, Nicholas" sort="Iannotti, Nicholas" uniqKey="Iannotti N" first="Nicholas" last="Iannotti">Nicholas Iannotti</name><name sortKey="Moy, Beverly" sort="Moy, Beverly" uniqKey="Moy B" first="Beverly" last="Moy">Beverly Moy</name><name sortKey="Robert, Nicholas J" sort="Robert, Nicholas J" uniqKey="Robert N" first="Nicholas J" last="Robert">Nicholas J. Robert</name><name sortKey="Rodriguez, Gladys" sort="Rodriguez, Gladys" uniqKey="Rodriguez G" first="Gladys" last="Rodriguez">Gladys Rodriguez</name><name sortKey="Smith, John" sort="Smith, John" uniqKey="Smith J" first="John" last="Smith">John Smith</name><name sortKey="Wong, Alvin" sort="Wong, Alvin" uniqKey="Wong A" first="Alvin" last="Wong">Alvin Wong</name><name sortKey="Yao, Bin" sort="Yao, Bin" uniqKey="Yao B" first="Bin" last="Yao">Bin Yao</name><name sortKey="Ye, Yining" sort="Ye, Yining" uniqKey="Ye Y" first="Yining" last="Ye">Yining Ye</name></country><country name="Japon"><noRegion><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name></noRegion><name sortKey="Masuda, Norikazu" sort="Masuda, Norikazu" uniqKey="Masuda N" first="Norikazu" last="Masuda">Norikazu Masuda</name></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Harvey, Vernon J" sort="Harvey, Vernon J" uniqKey="Harvey V" first="Vernon J" last="Harvey">Vernon J. Harvey</name></noRegion></country><country name="Croatie"><noRegion><name sortKey="Silovski, Tajana" sort="Silovski, Tajana" uniqKey="Silovski T" first="Tajana" last="Silovski">Tajana Silovski</name></noRegion></country><country name="Turquie"><noRegion><name sortKey="Gokmen, Erhan" sort="Gokmen, Erhan" uniqKey="Gokmen E" first="Erhan" last="Gokmen">Erhan Gokmen</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Von Minckwitz, Gunter" sort="Von Minckwitz, Gunter" uniqKey="Von Minckwitz G" first="Gunter" last="Von Minckwitz">Gunter Von Minckwitz</name></noRegion></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Ejlertsen, Bent" sort="Ejlertsen, Bent" uniqKey="Ejlertsen B" first="Bent" last="Ejlertsen">Bent Ejlertsen</name></region></country><country name="Canada"><noRegion><name sortKey="Chia, Stephen K L" sort="Chia, Stephen K L" uniqKey="Chia S" first="Stephen K L" last="Chia">Stephen K L. Chia</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Mansi, Janine" sort="Mansi, Janine" uniqKey="Mansi J" first="Janine" last="Mansi">Janine Mansi</name></region></country><country name="Brésil"><region name="Rio Grande do Sul"><name sortKey="Barrios, Carlos H" sort="Barrios, Carlos H" uniqKey="Barrios C" first="Carlos H" last="Barrios">Carlos H. Barrios</name></region></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Gnant, Michael" sort="Gnant, Michael" uniqKey="Gnant M" first="Michael" last="Gnant">Michael Gnant</name></region></country><country name="Belgique"><noRegion><name sortKey="Buyse, Marc" sort="Buyse, Marc" uniqKey="Buyse M" first="Marc" last="Buyse">Marc Buyse</name></noRegion></country><country name="République tchèque"><region name="Moravie"><name sortKey="Petrakova, Katarina" sort="Petrakova, Katarina" uniqKey="Petrakova K" first="Katarina" last="Petrakova">Katarina Petrakova</name></region></country><country name="Espagne"><noRegion><name sortKey="Zotano, Angel Guerrero" sort="Zotano, Angel Guerrero" uniqKey="Zotano A" first="Angel Guerrero" last="Zotano">Angel Guerrero Zotano</name></noRegion><name sortKey="Martin, Miguel" sort="Martin, Miguel" uniqKey="Martin M" first="Miguel" last="Martin">Miguel Martin</name></country><country name="Italie"><noRegion><name sortKey="Tassone, Pierfrancesco" sort="Tassone, Pierfrancesco" uniqKey="Tassone P" first="Pierfrancesco" last="Tassone">Pierfrancesco Tassone</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26874901
|texte= Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26874901" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |